Harmonic Pharma is seeking partners to co-develop or license out its current portfolio of repositioned drugs in three therapeutic areas:• Oncology : lung cancers and eye melanoma as target indications. A strategic R&D partnership of several years with the Institut Curie, a world-leading anti-cancer center, aimed at developing the company’s patented molecules e.g. HPH112 and HPH211
Harmonic Pharma has developed a proprietary drug repositioning platform using spherical harmonic based shapes of safe drugs [Karaboga et al. 2013]. The resulting polypharmacology profile [Perez-Nueno et al. 2014], characterizes drugs that have already gone through extensive preclinical testing and shown safety in their original indication. The process is completed with in vitro assays and in vivo validations performed with pathophysiological models pertinent to human diseases to give rise to a suitable therapeutic window in the identified new indication. Drugs are subsequently patented in their novel therapeutic use to be licensed out or co-developed.